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ABSTRACT 21 
Molecular methods offer superior sensitivity and specificity, and reduce testing turnaround time 22 
from days to hours for detection of Bordetella pertussis and Bordetella parapertussis. In this 23 
study, we evaluated the performance of the automated PCR-based ARIES Bordetella Assay, 24 
which detects both B. pertussis and B. parapertussis directly from nasopharyngeal swab 25 
specimens. Limits of detection were 1,800 colony-forming units/mL (CFU∙mL-1) for B. pertussis 26 
and 213 CFU∙mL-1 for B. parapertussis. The assay detected 16/18 unique B. pertussis / B. 27 
parapertussis strains. Of 71 potential cross-reacting organisms, 5 generated false-positives in 1/6 28 
replicates; none of 6 additional Bordetella spp. were erroneously detected. Specimens were 29 
stable at 20−25°C for at least 10 h, 4−8°C for 10 days, and at ≤ -70°C for 6 months. Of 1,052 30 
nasopharyngeal specimens from patients with suspected pertussis, 3.0% (n=32) were B. 31 
pertussis-positive, and 0.2% (n=2) were B. parapertussis-positive. After combining these data 32 
with ARIES Bordetella Assay data from 57 nasopharyngeal samples with previously confirmed 33 
B. pertussis or B. parapertussis, and from 50 contrived B. parapertussis samples, ARIES assay 34 
respective positive and negative percent agreements with the reference assays were 97.1% and 35 
99.0% for B. pertussis, and 100% and 99.7% for B. parapertussis. The ARIES Bordetella Assay 36 
provides accurate detection and distinction of B. pertussis and B. parapertussis infection within 2 37 
hours.  38 
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Introduction 39 
Pertussis, or whooping cough, is a highly contagious respiratory disease caused by the Gram-40 
negative bacteria Bordetella pertussis and Bordetella parapertussis. In some patients, especially 41 
infants and young children, infection with these organisms can lead to potentially life-threatening 42 
complications such as pneumonia, weight loss, dehydration, and seizures. Although there is a 43 
vaccine to prevent disease caused by B. pertussis, an estimated 24.1 million cases and over 44 
160,000 deaths, mainly in infants and children less than 5 years old, are recorded annually 45 
worldwide (1). In the US, pertussis prevalence has risen since the 1980s, with cyclical peaks 46 
occurring every 3–5 years (2). In 2012, the most recent peak year, the Centers for Disease 47 
Control and Prevention (CDC) identified 48,277 cases nationwide, though more cases were 48 
likely undiagnosed. In 2016, the most recent year with complete statistics, the CDC confirmed 49 
nearly 18,000 cases in the US (3). 50 
Disease signs and symptoms caused by these two pathogens are similar; however, those 51 
associated with B. parapertussis infection are often milder and disease duration is generally 52 
shorter (4−7). Both pathogens cause biphasic symptoms that appear following a 5–10-day 53 
incubation period. A 7–10-day prodromal stage, the catarrhal stage resembling coryza, 54 
progresses to classic pertussis symptoms, which include paroxysmal coughing followed by high-55 
pitched “whooping” during inspiration of air against narrowed airways, and sometimes post-56 
tussive emesis. In adults, signs and symptoms can persist for several weeks. Early and accurate 57 
diagnosis of pertussis is essential for the optimization of therapy and to curb the transmission of 58 
these pathogens (5−7).  59 
Distinguishing between these two pathogens is important from a public health 60 
perspective, because B. parapertussis may cause up to 20% of pertussis-like disease in young 61 
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children, and co-infection with B. pertussis is common (4−7). Contemporary options for the 62 
detection of B. pertussis and B. parapertussis infections include immunoserological tests to 63 
detect either bacterial antigens in respiratory specimens or pathogen-specific antibodies in serum, 64 
culture of nasopharyngeal specimens using specialized media, and nucleic acid amplification 65 
tests to detect B. pertussis and B. parapertussis DNA in nasopharyngeal swab and aspirate 66 
specimens (5−7). Although culture affords excellent specificity (nearly 100%), it requires up to 7 67 
days to obtain results, is often labor-intensive, and can have poor sensitivity, especially if 68 
specimens were obtained after the initiation of antimicrobial therapy. Also, culture is most 69 
successful during the first 1−2 weeks following cough onset in unvaccinated patients that have 70 
not received antibiotics (7). Serologic tests for pertussis infection can be helpful, but have limited 71 
utility early after infection, and no commercial kits have been approved by the U.S. Food and 72 
Drug Administration (FDA) for diagnostic use (8). Molecular assays for detection of B. pertussis 73 
and B. parapertussis detection are much faster than culture, offer higher sensitivity, are 74 
continuously improving in test turnaround time and protocol simplification, and have received 75 
FDA clearance. The CDC Best Practices guidelines indicate that PCR-based assays are 76 
recommended as first-line approaches for diagnosing pertussis in symptomatic patients (9).  77 
The ARIES Bordetella Assay (Luminex Corp., Austin, TX) is an automated nucleic acid 78 
amplification assay that is designed to rapidly, simultaneously, and differentially identify B. 79 
pertussis and B. parapertussis in nasopharyngeal swab specimens. The assay detects the 80 
pertussis toxin (ptxA) promoter and IS1001 of B. pertussis and B. parapertussis, respectively. 81 
The current study evaluated the analytical performance of the ARIES Bordetella Assay system 82 
by conducting a large-scale multi-site evaluation of the assay using clinical specimens obtained 83 
from subjects with suspected and/or known pertussis infection. 84 
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MATERIALS AND METHODS 85 
Clinical study design. 86 
Inclusion Criteria and Study Oversight. Inclusion criteria were subjects: i) with signs and 87 
symptoms consistent with B. pertussis and/or B. parapertussis infection; ii) for whom a 88 
Bordetella test had been requested; and iii) who provided a nasopharyngeal swab specimen 89 
collected in Universal Transport Medium (UTM) with volume ≥1,000 µL. Specimens were 90 
excluded if subjects had antibiotic use within 24 h of specimen collection.  91 
Clinical specimens were exempted from informed consent requirements by the 92 
Institutional Review Board at all participating sites per FDA advisory Guidance on Informed 93 
Consent for In Vitro Diagnostic Device Studies using Leftover Human Specimens that are not 94 
Individually Identifiable, January 2006 (10); results were not used for patient management. 95 
Chart review data were anonymized before compilation and analysis. This study was registered 96 
on ClinicalTrials.gov (NCT02862262), and conformed to the Declaration of Helsinki and the 97 
Health Insurance Portability and Accountability Act. 98 
 99 
Specimens. Diagnostic accuracy of the ARIES Bordetella Assay was evaluated in 1,053 100 
prospectively collected, de-identified nasopharyngeal swab specimens from subjects presenting 101 
with suspected B. pertussis or B. parapertussis infection at five geographically diverse sites in 102 
the United States (New Mexico, Wisconsin, Ohio, Michigan, and Indiana) between July and 103 
November, 2015. The Ohio samples were assayed at the New Mexico site. Investigators, 104 
technicians performing Bordetella testing, and the study sponsor were masked with respect to 105 
specimen identification. Swab specimens were collected in UTM, refrigerated at 2−8ºC within 4 106 
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h of collection, and specimen aliquots (≥250 µL) were stored at 2−8ºC (and tested within 72 h) 107 
or frozen at -70ºC for testing at a later time. 108 
 109 
Study Groups. This clinical study comprised three study arms. Arm 1 was the blinded 110 
prospective evaluation of nasopharyngeal swabs collected from subjects with symptoms of B. 111 
pertussis or B. parapertussis infection, but without accompanying diagnostic information. We 112 
estimated B. pertussis to be present in 5% of samples in Arm 1. Because this frequency was not 113 
guaranteed, per protocol we generated a second arm, Arm 2, containing additional banked pre-114 
selected known Bordetella-positive swab specimens (37 B. pertussis and 20 B. parapertussis) 115 
and an equal number (n=57) of unique B. pertussis-negative/B. parapertussis-negative clinical 116 
specimens from study sites. All Arm 2 samples had been stored frozen and were evaluated in 117 
random order. Because B. parapertussis is particularly rare, and we wished to accurately 118 
estimate positive and negative percent agreement (PPA and NPA, respectively) between the 119 
ARIES and reference assays, Arm 3 contained 50 contrived specimens that were spiked with B. 120 
parapertussis strains at clinically-relevant titers, and tested in random order among 50 negative-121 
control specimens. 122 
 123 
ARIES Bordetella Assay operation. All study sites used the ARIES system with Bordetella 124 
Assay Cassettes (Luminex) and ARIES Bordetella Assay Protocol Source File-IUO v.5. 125 
Analysis software was SyncT ARIES UDP Desktop Software, Version 1.1 Build 165 (Luminex). 126 
Four specimen aliquots (≥250 µL) were stored at 2−8ºC, and tested within 72 h of collection or 127 
frozen (-65°C to -95°C), per manufacturer instructions (11). External positive-controls included 128 
pooled B. pertussis A639 and B. parapertussis A747 cultures diluted in Natural Negative 129 
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Nasopharyngeal Matrix (NPM); negative-controls were vehicle-only. The assay cassettes contain 130 
extractable Sample Processing Controls to assess PCR extraction and amplification fidelity. 131 
Specimens testing negative for Bordetella were required to have a positive result for these 132 
internal controls (cycles, Ct; and melting temperature, Tm) for the negative result to be validated. 133 
 134 
Comparator assays. One frozen aliquot was shipped on dry ice to Luminex Molecular 135 
Diagnostics (Toronto, ON) for comparator testing, with two frozen aliquots remaining on site as 136 
reserves. All ARIES assay results, whether positive or negative, were confirmed by two real-time 137 
PCR assays per organism (total = 4 PCR assays), with results validated by conventional 138 
(endpoint) PCR amplification followed by bidirectional sequencing of the amplicons, in 139 
accordance with FDA guidance. The reference real-time PCR assays for B. pertussis and B. 140 
parapertussis targeted unique regions of the ptxA gene promoter and IS1001 insertion sequence, 141 
respectively, which differed from the regions targeted by the ARIES assay. Specimens were 142 
considered positive for B. pertussis or B. parapertussis if one or both comparator PCR assays 143 
was positive (Ct values ≤40) and confirmed by bidirectional sequencing. All samples from all 144 
three arms were evaluated using the ARIES system, as well as by the comparator assays. 145 
Arm 1 samples had previously been tested by each site using their in-house standard-of-146 
care (SOC) assay. Each site used their own laboratory-developed real-time PCR assay targeting 147 
IS481 and IS1001 for B. pertussis and B. parapertussis, respectively, with initial findings 148 
remaining undisclosed until study terminus. Two study sites performed a laboratory-developed 149 
test (LDT) using Luminex MultiCode Analyte Specific Reagents, one site used a TaqMan-based 150 
(Thermo-Fisher; Foster City, CA) LDT, and one site used DiaSorin reagents (DiaSorin; Cypress, 151 
CA) for their LDT. 152 
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 153 
Analytical performance overview. The AIRES Bordetella Assay was evaluated for limit-of-154 
detection (LoD), intra-lab/inter-operator and site-to-site reproducibility, detectability of multiple 155 
B. pertussis and B. parapertussis strains, potential interfering substances and microorganisms, 156 
run-to-run carryover, swab and media interference effects, and sample stability during storage, 157 
with outcomes detailed in the Luminex AIRES Bordetella Assay 510(k) FDA Decision Summary 158 
(12). Reference bacterial strains B. pertussis A639 and B. parapertussis A747 from 159 
(ZeptoMetrix, Buffalo, NY) were used in all assays except where noted. Dilution medium and 160 
vehicle-only negative-controls were NPM, derived from nasopharyngeal swab extracts pooled 161 
from 242 asymptomatic individuals (BioIVT, Westbury, NY) or UTM, unless otherwise 162 
indicated. Data points are the average of triplicate determinations for a given condition, unless 163 
otherwise noted. 164 
 165 
Limit of detection. Six 20-fold serial dilutions of two B. pertussis strains (A639 and ATCC 166 
BAA-589) and two B. parapertussis strains (A747 and ATCC BAA-587 [ATCC, Manassas, 167 
VA]) in NPM were assayed to estimate the LoD; this concentration was subsequently tested in 168 
20 replicates, and the analytical LoD was defined as the concentration in CFUs that had ≥95% 169 
positive detection rate. 170 
 171 
Cross reactivity. Cross-reactivity of the ARIES Bordetella Assay was evaluated in 18 strains of 172 
B. pertussis and B. parapertussis in samples created with 3×LoD, 10×LoD, and 100×LoD of 173 
these organisms (Supplementary Table S1). We also evaluated erroneous detection of high-174 
concentration suspensions (in NPM) of 71 non-B. pertussis/B. parapertussis potential cross-175 
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reacting organisms (CROs), many of which cause infections with symptoms resembling those of 176 
Bordetella infection (12). This included six additional Bordetella species, including 4 strains 177 
each of B. bronchiseptica and B. holmesii, at concentrations ranging between 1.0×10
6 
CFU∙mL-1 178 
to 1.9×10
6 
CFU∙mL-1. 179 
Microbial interference was evaluated by adding the same potential CROs at the same 180 
concentrations as in cross-reactivity testing to B. pertussis and B. parapertussis suspensions 181 
containing 3×LoD of either target Bordetella pathogen. Cross-target interference in simulated co-182 
infection scenarios was assessed by assaying suspensions containing 100×LoD of both target 183 
organisms (high/high) or 3×LoD of both (low/low). For high/low co-infection testing, high 184 
concentrations (≥106 CFU∙mL-1) of B. pertussis or B. parapertussis were spiked into 3×LoD 185 
suspensions of the other Bordetella species. 186 
 187 
Specimen stability. We evaluated positive detection of 3×LoD B. pertussis and B. parapertussis 188 
samples suspended in NPM that were stored at 20 - 25°C for 0, 2, 4, 8 and 10 h, or at 4 - 8°C for 189 
0, 1, 3, 7, and 10 days, or after storage at -70°C for up to 6 months (n=3 samples per timepoint 190 
under each condition). In a separate experiment, suspensions of B. pertussis or B. parapertussis 191 
(3×, 10×, and 100×LoD) were assayed immediately or after freezing at -70°C for 2 days (15‒30 192 
replicates per condition/time). In total, 214 specimens were evaluated by the clinical testing sites 193 
for stability under freezing conditions (114 from the Arm 2 prospectively collected samples and 194 
100 from the Arm 3 pre-selected retrospective samples). 195 
 196 
Statistical analysis. To ensure sufficient statistical power, we calculated the required number of 197 
prospectively collected specimens to achieve ≥95% sensitivity with a lower bound of the 198 
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two-sided 95% confidence interval (CI) >85%. Based on an estimated B. pertussis prevalence of 199 
approximately 5% in the intended population, we calculated that 1,000 specimens were needed 200 
to obtain ≥50 positive specimens. Data are presented as n (%) or value ± 95%CIs, as indicated. 201 
Positive and negative percent agreement (PPA and NPA, respectively) of the ARIES assay with 202 
comparator assays were derived from 2×2 contingency tables, with minimum desired ≥95% PPA 203 
with lower bound of two-sided 95%CI >85%. Statistical software included SyncT UDP desktop 204 
software v.1.1, build 165 (Luminex), SAS v.9.2 (SAS Corp, Cary, NC), and Prism v.5.0 205 
(GraphPad Software, La Jolla, CA). 206 
 207 
RESULTS 208 
Clinical trial subject and specimen accounting. A total of 1,053 unique nasopharyngeal swab 209 
specimens from 1,053 subjects presenting with pertussis-like disease were collected at five study 210 
sites during July – November 2015. Individual sites provided between 25–427 (2‒41%) of total 211 
prospective Arm 1 samples. One specimen was excluded from performance calculations due to 212 
refrigerator storage >72 h, leaving 1,052 evaluable specimens. Most subjects (74%) were 213 
<18-years-old, 56% were female, and nearly 74% visited outpatient clinics (Table 1). ARIES 214 
testing was performed on 63.4% of samples (n=667) within 72 h of storage at 4–8°C; the 215 
remaining 36.6% (n=385) were stored frozen at -70°C for up to 12 days prior to assay.  216 
 217 
Comparison to SOC results. After completing the clinical performance assessment of the study, 218 
we compared the results of the ARIES assay to the result initially obtained by each site using 219 
their SOC test method. Of the 1,052 evaluated specimens in Arm 1, 23 samples were negative 220 
for B. pertussis by ARIES and by the ARIES-positive comparator sequencing assay, but had 221 
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initially tested B. pertussis-positive by the study sites’ in-house SOC assay for IS481. These 222 
samples were further tested by Luminex using a validated high-sensitivity endpoint nested-PCR 223 
assay, followed with bidirectional sequencing for B. pertussis using primers targeting regions 224 
distinct from those used in the ARIES assay and in the clinical trial comparator sequencing 225 
assay, to reassess B. pertussis. In addition, validated single-plex real-time PCR assays and 226 
bidirectional sequencing were performed for B. holmesii and B. bronchiseptica. Of the 23 227 
discordant specimens, this analysis identified 5 B. pertussis-positive and 3 B. holmesii-positive 228 
specimens (Table 3). 229 
 230 
Clinical performance. Of 1,052 unique specimens in prospective Arm 1, 1,043 (99.1%) yielded 231 
valid results on the first run. The remaining 9/1,052 (0.9%) initially produced invalid results due 232 
to run failure or instrument error, but generated valid results (positive or negative) upon re-233 
testing. The ARIES assay produced 30 positive B. pertussis results and 1,011 negative results 234 
(Table 2). Compared to the PCR/sequencing comparator controls, the PPA for B. pertussis 235 
detection was 93.8% and the NPA was 98.9%. For B. parapertussis detection, the ARIES assay 236 
identified two positives in this population, yielding a PPA of 100% and an NPA of 98.9%. 237 
Because the observed prevalences of B. pertussis and B. parapertussis in the prospective study 238 
were lower than expected (3.0%, 32/1,052; and 0.2%, 2/1,052, respectively), the initial study 239 
design (Arm 1, prospective) did not achieve the desired minimum criteria of ≥95% PPA with a 240 
lower bound of the two-sided 95% CI >85%. Per protocol, we supplemented this sample set with 241 
pre-selected specimens that tested positive for B. pertussis and B. parapertussis by comparator 242 
assays (Arm 2; pre-selected). In addition, we tested B. parapertussis suspensions at clinically 243 
relevant titers (Arm 3, contrived). 244 
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Percent agreement to a reference method in part depends on the frequency of the studied 245 
pathogen. To increase Bordetella frequency, a set of 57 pre-selected nasopharyngeal swabs (37 246 
for B. pertussis and 20 for B. parapertussis) were obtained from study sites that had been 247 
previously characterized as positive for these pathogens. These Arm 2 samples underwent 248 
ARIES Bordetella testing at 3 study sites, with comparator real-time PCR and bidirectional 249 
sequencing performed at Luminex. An equal number of clinical samples negative for B. pertussis 250 
and B. parapertussis (n=57) were included as controls. All specimens were anonymized and their 251 
order of analysis was randomized. The PPA for B. pertussis in the 37 pre-selected samples was 252 
100%, with a lower bound of the 95% CI: 90.5%; the NPA was also 100%, with lower 95% CI 253 
bound: 95.3% (Table 2). In the 20 pre-selected B. parapertussis samples, the PPA was 100%, 254 
although the lower 95% CI bound was 83.2%; the NPA was 99% with the lower 95% CI bound: 255 
98.9%. In 50 contrived B. parapertussis samples in Arm 3, both PPA and NPA were 100%, with 256 
the lower CI bound satisfying the desired criterion (Table 2). After pooling results from all study 257 
arms, the PPA and NPA for both B. pertussis and B. parapertussis satisfied all pre-defined 258 
acceptability criteria. 259 
 260 
LoD. The LoD was defined as the lowest concentration of Bordetella that was detectable in ≥ 261 
95% of 20 replicates. In B. pertussis strains A639 and BAA-589, LoDs were 1,640 CFU∙mL-1 262 
and 1,800 CFU∙mL-1; in B. parapertussis strains A747 and BAA-587, LoDs were 172 CFU∙mL-1 263 
and 213 CFU∙mL-1, respectively. Thus, 1,800 CFU∙mL-1 and 213 CFU∙mL-1 were considered to 264 
be the LoDs for B. pertussis and B. parapertussis, respectively. 265 
 266 
 o
n
 April 22, 2020 by guest
http://jcm.asm.org/
D
ow
nloaded from
 
13 
 
Cross-reactivity. Of the 71 unique potential CROs tested alone, 66 were non-reactive with the 267 
ARIES Bordetella Assay at high titers, including 4 strains each of B. bronchiseptica and B. 268 
holmesii (12). All of the 5 CROs (Fusobacterium necrophorum and Proteus vulgaris for B. 269 
pertussis, and human coronavirus OC43, influenza B virus, and Moraxella catarrhalis for B. 270 
parapertussis) generated a false-positive in 1/3 replicates each, all with late Cts (38−40 cycles); 271 
no cross-reactivity was observed when these CROs were assayed in 3 additional replicates. 272 
Cross-reactivity of the ARIES Bordetella Assay was also evaluated in 18 strains of B. 273 
pertussis and B. parapertussis (Supplementary Table S1). Nine of 11 (81.8%) B. pertussis strains 274 
were detected at 100% positivity at 3×LoD while two B. pertussis strains, ATCC 8478 and 275 
ATCC 9797, were not detected at up to 100×LoD. All seven B. parapertussis strains were 276 
detected at 100% positivity when tested at 3×LoD. 277 
In interference assays with Bordetella suspensions spiked with CROs, B. pertussis was 278 
correctly detected in 3/3 (100%) replicates in the presence of 66 CROs. Five CROs in total, B. 279 
bronchiseptica (strains 1 and 2), Bordetella petrii, Klebsiella aerogenes, and Klebsiella 280 
pneumoniae required testing of 3 additional replicates, per protocol. For these 5 CROs, B. 281 
pertussis was detected in 5/6 (83.3%) replicates. B. parapertussis was correctly detected in 3/3 282 
(100%) replicates when tested in presence of all 71 CROs. 283 
Microbial interference was also evaluated in simulated B. pertussis/B. parapertussis co-284 
infection settings with variable ratios of B. pertussis to B. parapertussis (e.g., high [100×LoD] 285 
-low [3×LoD], low-high, high-high, and low-low). All replicates in all combinations yielded 286 
expected positivity for B. pertussis and B. parapertussis (12). The overall invalid rate was 0.9% 287 
(7/744) during the microbial interference and cross-reactivity study; all invalids were re-run and 288 
gave the expected result. 289 
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 290 
Specimen stability. One-hundred percent of both B. pertussis- and B. parapertussis-positive 291 
(3×LoD) and NPM-only negative controls were accurately distinguished after storage at 20‒292 
25°C for at least 10 hours, 4‒8°C for at least 10 days, and -70°C for up to 6 months (n=3 samples 293 
per timepoint under each condition; not shown). No differences were seen in detection of 294 
identical suspensions of B. pertussis or B. parapertussis (3×, 10×, and 100×LoD) that were 295 
assayed immediately after production or after freezing at -70°C for 2 days (12). 296 
 297 
DISCUSSION 298 
This study characterized the performance of the ARIES Bordetella Assay for identifying 299 
and differentiating B. pertussis and B. parapertussis in nasopharyngeal swabs from patients with 300 
suspected or known pertussis. Whereas microbiological culture of nasopharyngeal swab or 301 
aspirate samples is the most specific means of detecting and delineating B. pertussis and B. 302 
parapertussis, these pathogens can be fastidious to grow in vitro and frequently require 5–7 days 303 
to acquire results (5‒7, 13). This time lag delays implementation of appropriate antimicrobial 304 
therapy and infection control measures, often when the infected individual is most contagious (2, 305 
3). While the World Health Organization (WHO) surveillance guidelines still include paired 306 
serology as a B. pertussis diagnostic measure, this requires that sequential sampling and testing 307 
occur at least 1 week apart (14), conferring the same delay in obtaining results that occurs with 308 
culture. The CDC does not recognize a role for serological testing in its pertussis surveillance 309 
guidelines (7) and essentially all current Bordetella surveillance guidelines concur on the evident 310 
utility of nucleic acid amplification testing as a first-line approach for diagnosing Bordetella 311 
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infection (9, 14, 15). The ARIES Bordetella Assay accurately identifies two primary Bordetella 312 
pathogens in less than 2 hours. 313 
Molecular diagnostic tests for identifying Bordetella species in nasopharyngeal swabs 314 
and aspirates are more sensitive than serological testing, provide faster results than culture, and 315 
are applicable to specimens collected up to 3 weeks after the onset of cough. Nucleic acid 316 
amplification assays can potentially match culture’s high specificity and ability to 317 
simultaneously identify the presence of multiple Bordetella species (9, 16‒18). The B. 318 
parapertussis infection rate is increasing, thought in part to be due to a competitive advantage 319 
conferred by vaccination against BP (4, 6, 19). The overlapping symptomatology caused by B. 320 
pertussis and B. parapertussis increases the importance of being able to confidently identify and 321 
differentiate these two most common human-pathogenic Bordetella species. 322 
The ARIES Bordetella Assay consistently detected the presence of low titers of 9 B. 323 
pertussis and 7 B. parapertussis strains. Two B. pertussis strains that went undetected contained 324 
similar nucleotide mismatches in the ARIES primer binding regions (19), which presumably 325 
hindered assay detection of these strains. A search of the National Center for Biotechnology 326 
Information database revealed a very low (2.9%) prevalence of two similarly mismatched B. 327 
pertussis strains, both collected over a decade ago, and only one of which is known to have a 328 
human origin. This suggests a current paucity of similar mismatched B. pertussis strains 329 
circulating in the human population. Coinfection with B. pertussis and B. parapertussis occurs 330 
and might affect both treatment and outcome (20, 21). The ARIES assay was able to detect both 331 
of these organisms at low titers in the presence of extremely high concentrations of the sister 332 
pathogen, thereby demonstrating utility for accurately characterizing the most likely Bordetella 333 
species coinfection scenarios.  334 
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The ARIES Bordetella Assay has a low likelihood of falsely detecting a potential CRO as 335 
B. pertussis or B. parapertussis, or of a CRO interfering with intended B. pertussis/B. 336 
parapertussis detection, even near the Bordetella species’ LoDs. The single-copy ptxA gene is 337 
present only in B. pertussis, which confers increased specificity to the ARIES assay in accurately 338 
diagnosing true pertussis compared to nucleic acid assays that target IS481, a multi-copy gene 339 
that is also present in the confounding pathogens B. holmesii and some strains of B. 340 
bronchiseptica (22−25). Of other currently FDA-cleared B. pertussis diagnostic assays, one 341 
system (FilmArray RP and RP2; BioFire Diagnostics) targets the ptxA gene, while another 342 
(Illumigene; Meridian Bioscience) targets the IS481 gene and is known to additionally detect B. 343 
holmesii and B. bronchiseptica (26, 27). 344 
The ARIES assay identifies B. parapertussis by detecting IS1001, present at 345 
approximately 20 copies per genome (17). Although IS1001 has been reported in occasional 346 
strains of B. bronchiseptica (4/73 human isolates), this low expression level coupled with the 347 
very rare involvement of this organism in suspected pertussis outbreaks makes it unlikely to be a 348 
meaningful impediment to ARIES diagnostic utility (23, 28). The BioFire RP2 also evaluates 349 
IS1001; the Illumigene does not assess B. parapertussis. B. bronchiseptica was not detected in 350 
any sample in the current study. 351 
Of 71 potential CROs assayed, 66 (93%) were not detected by ARIES. Two organisms 352 
produced a single false-positive for B. pertussis that was not replicated in triplicate re-testing; 353 
similarly, three CROs generated a single false-positive for B. parapertussis that was not 354 
repeatable. Human specimens and contrived samples remained stable during common storage 355 
temperatures and durations. Together these observations demonstrate the ARIES assay’s 356 
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reliability in selectively identifying low titers of the two most common Bordetella pathogens in 357 
diverse testing scenarios.  358 
 We reconciled ARIES findings by comparison to results from two unique real-time PCR 359 
reference assays for each pathogen (four assays total), supplemented with bidirectional 360 
sequencing of PCR amplicons when either one or both of the two PCR assays (per organism) 361 
was positive. In the prospective arm, 99.1% of specimens (1,043/1,052) yielded valid results on 362 
the first attempt, and remaining nine samples provided a definitive conclusion when retested. 363 
Because our population contained lower than the estimated B. pertussis incidence of 5%, we 364 
supplemented our sample set with known B. pertussis-positive (n=37) or B. parapertussis-365 
positive (n=20) clinical samples to increase pathogen frequency; all were accurately assessed by 366 
the ARIES Bordetella Assay. Because B. parapertussis-positive samples were expectedly lower 367 
in number than B. pertussis-positive samples, we also included 50 contrived B. parapertussis 368 
specimens to increase the accuracy of our percent agreement calculations, along with appropriate 369 
vehicle-only controls, all of which were also accurately identified. The ARIES’ cumulative PPA 370 
and NPA exceeded the minimum acceptable performance criteria by a substantial margin. The 371 
respective PPAs for B. pertussis and B. parapertussis were 97.1% and 100%, with lower 95% CI 372 
bounds above the minimum 85% specification for both organisms. The respective NPAs for B. 373 
pertussis and B. parapertussis were 99.0% and 99.7%, respectively, again with lower 95% CI 374 
bounds above 85% for both species. Thus, the diagnostic accuracy of the ARIES Bordetella 375 
Assay is acceptable for effectively detecting BP and BPP in nasopharyngeal swabs from patients 376 
suspected of having respiratory tract infection attributable to either pathogen.  377 
 Initial SOC testing performed by each study site produced 23 cases of putative B. 378 
pertussis infection in Arm 1 (23/1,502=1.5%) that were not detected as B. pertussis-positive by 379 
 o
n
 April 22, 2020 by guest
http://jcm.asm.org/
D
ow
nloaded from
 
18 
 
ARIES or by the bidirectional sequencing comparator. All study sites used PCR assays that 380 
targeted IS481, an insertion sequence present in high copy number in B. pertussis (≥50 381 
copies/genome) but that is also present in B. holmesii at a lower copy number (e.g., 8‒10 382 
copies/genome) (22, 25). Highly sensitive follow-up testing of the 23 discordant samples 383 
identified 5 additional B. pertussis-positive specimens, 3 B. holmesii-positive specimens, and 15 384 
confirmed Bordetella-negative samples. This reflects the utility of IS481 assays as a sensitive 385 
screening tool for B. pertussis, but also highlights its limited diagnostic specificity that can 386 
potentially misidentify other less insidious Bordetella spp. as true pertussis. For example, B. 387 
holmesii was present in up to 20% of suspected pertussis cases during a 2009‒2011 outbreak in 388 
France (29). Whereas only approximately 5% of B. bronchiseptica strains reportedly express 389 
IS481, a commonly used primer set used for PCR detection of IS481 erroneously produced 390 
diagnostic amplicons of the predicted size for this gene in 78% of 149 tested B. bronchiseptica 391 
isolates, including in 22/24 that were of human origin (24). The IS481 assay may also produce 392 
false-positive B. pertussis findings by detecting high-copy IS481 DNA on lightly contaminated 393 
laboratory surfaces (30), or even from aerosolized pertussis vaccines in the clinic setting in the 394 
absence of viable organisms being present in samples (31). Interestingly, 12/15 (80%) of the 395 
study site SOC IS481-positive samples that ultimately tested negative for B. pertussis had initial 396 
IS481 Ct values >35.0 (Table 3), suggesting that it detected a low total starting target sequence 397 
copy number. Together, these limitations of IS481-based assays may be responsible for 398 
identifying pertussis pseudo-outbreaks that do not truly constitute public health emergencies 399 
(32), and may constitute more of a public health concern than the low false-negative rate using 400 
the ptxA-based ARIES assay.  401 
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 Study strengths include the multicenter prospective design, a large initial clinical sample 402 
size and the availability of supplemental known-positive BP and BPP clinical samples necessary 403 
to increase the accuracy of PPA and NPA determinations in low-frequency illnesses, particularly 404 
with BPP, and the availability of three robust reference techniques for comparison with ARIES 405 
findings. Study limitations include the inability of the qualitative ARIES assay to discern 406 
symptomatic, subclinical, and resolving Bordetella infection, although the likelihood of 407 
misidentifying an active infection is negated by judicious evaluation of clinical symptoms (5‒7). 408 
The low natural prevalence of B. pertussis and B. parapertussis in the prospectively collected 409 
samples required inclusion of additional specimens with known Bordetella PCR outcomes or the 410 
use of contrived samples. Because the ARIES assay targets genetic sequences specific to B. 411 
pertussis and B. parapertussis, it is unable to identify the two other Bordetella species that can 412 
cause pertussis-like symptoms in humans, i.e., B. bronchiseptica and B. holmesii, although 413 
infection with these organisms is comparatively rare (4‒6). 414 
  The ARIES system can simultaneously evaluate up to 12 samples with minimal hands-on 415 
time required during its 2-hour runtime. The self-contained assay cartridges contain all reaction 416 
components and an internal sample processing control to monitor PCR fidelity. This study 417 
demonstrated that the ARIES Bordetella diagnostic assay reproducibly and accurately detects 418 
and discerns the two most clinically relevant Bordetella species that cause pertussis-like disease. 419 
 420 
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Table 1 Demographics of the clinical study population in prospective Arm 1. 
Gender Site 1 Site 2 Site 3 Site 4 Site 5 All Sites 
Male 56 (40.9%) 180 (42.3%) 56 (45.2%) 11 (44.0%) 164 (48.2%) 467 (44.4%) 
Female 81 (59.1%) 246 (57.7%) 68 (54.8%) 14 (56.0%) 176 (51.8%) 585 (55.6%) 
Age, yrs       
<18 76 (55.5%) 263 (61.7%) 92 (74.2%) 22 (88.0%) 326 (95.9%) 779 (74.0%) 
≥18 61 (44.5%) 163 (38.3%) 32 (25.8%) 3 (12.0%) 14 (4.1%) 273 (26.0%) 
Subjects by Site 137 424 124 25 339 1052 
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Table 2 ARIES Bordetella Assay PPA and NPA for B. pertussis and B. parapertussis detection 
versus comparator real-time PCR assays and bidirectional sequencing. 
 
  
aTwo prospective specimens generated false-negative results by ARIES Bordetella assay when compared to the 
composite comparator method. One of these two specimens gave a positive result in only one of two comparator 
real-time PCR assays. The other specimen generated Ct values between 37.1 and 38.8 by comparator real-time PCR 
assays; in this specimen, the ARIES Bordetella assay detected low levels of DNA (Ct=40.1), which was close to the 
assay cut-off. 
 
bOne pre-selected specimen generated a false-positive BPP result by ARIES Bordetella assay that was not 
confirmed by comparator real-time PCR and bi-directional sequencing. 
 
Bp, B. pertussis; Bpp, B. parapertussis; NPA, PPA, positive percent agreement; NPA, negative percent agreement; 
CI, confidence interval. 
 
 
 
 
Bp PPA 95% CI NPA 95% CI 
Prospective 
(Arm 1) 30/32
a
 93.8% 79.2%‒99.2% 1,009/1020 98.9% 98.1%‒99.5% 
Pre-selected 
(Arm 2) 37/37 100% 90.5%‒100% 77/77 100% 95.3%‒100% 
Total 67/69 97.1% 89.9%‒99.6% 1,086/1097 99.0% 98.2%‒99.5% 
 
Bpp PPA 95% CI NPA 95% CI 
Prospective 
(Arm 1) 2/2 100% 15.8%‒100% 1,048/1050 99.8% 99.3%‒100% 
Pre-selected 
(Arm 2) 20/20 100% 83.2%–100% 93/94b 98.9% 94.2%‒100% 
Contrived 
(Arm 3) 50/50 100% 92.9%‒100% 50/50 100% 92.9%‒100% 
Total 72/72 100% 95.0%‒100% 1,191/1194 99.7% 99.3%‒99.9% 
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Table 3  Reconciliation results of 23 discordant samples that were negative by ARIES for B. 
pertussis, but positive by each study site’s standard-of-care IS481 PCR assays. 
Study Site Sample Sequencing  Result  Site IS481 Assay Ct 
Site A 02-003 POS Bordetella pertussis* 
  
 
02-006 NEG  37.0 
 
02-007 POS Bordetella holmesii ⱡ 
  
 
02-037 POS Bordetella pertussis* 
  
 
02-059 NEG  37.3 
 
02-076 POS Bordetella pertussis* 
  
 
02-103 POS Bordetella pertussis* 
  
 
02-119 NEG  36.9 
 
02-165 NEG  36.5 
 
02-407 NEG  38.1 
 
02-501 NEG  38.6 
Site B 05-005 NEG  40.1 
 
05-013 NEG  38.5 
 
05-024 NEG  39.2 
Site C 06-031 NEG  36.7 
 
06-076 NEG  36.0 
 
06-125 POS Bordetella holmesii 
  
 
06-156 NEG  32.8 
 
06-172 NEG  31.2 
 
06-174 POS Bordetella pertussis 
  
 
06-179 POS Bordetella holmesii ⱡ 
  
 
06-314 NEG  33.5 
 
06-332 NEG  36.9 
* Detected in the forward read only 
 
ⱡ
 Detected in the reverse read only 
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